Literature DB >> 1245733

C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

M R Daha, D T Fearon, K F Austen.   

Abstract

C3 nephritic factor (C3NeF) defined by the capacity of nephritic serum and its fractions to initiate loss of the B antigen of C3 in normal serum was purified from the serum of three different donors and shown to function by stabilization of membrane-bound and fluid phase alternative pathway C3 convertase. C3NeF converts cell-bound C3B sites in a dose-related manner to CEB(NeF) sites, which exhibit an approximate 10-fold increase in half-life. The linear relationship between the C3NeF input and the residual hemolytic sites on EAC43B present after incubation for 20 min at 30 degrees C, during which labile C3B sites have decayed, indicates that the number of residual C3B sites is directly related to the dose of C3NeF. The capacity of C3NeF to stabilize the C3B convertase in a temperature- and dose-dependent manner, which is independent of binding or consumption of C3NeF, in a fluid phase reaction mixture of 125I-B, 131I-C3 and D permits isolation of a 10S complex containing radiolabeled C3 and B and exhibiting C3, convertase activity on an exogenous C3 source. Thus, the stabilizing effect of C3NeF is not limited to membrane-bound C3B but is also sufficient to permit recovery of a fluid phase C3 convertase formed during the interaction of C3, B, and D.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1245733

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  Identification of nephritic factor as an immunoglobulin.

Authors:  D G Williams; A Bartlett; P Duffus
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

Review 2.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

3.  Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.

Authors:  M A Marín; G Fontán; M López-Trascasa
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

Review 4.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

5.  Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3.

Authors:  M R Daha; L A van Es
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

6.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes; A Cats
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

Review 7.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

8.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  Detection of complement activation using monoclonal antibodies against C3d.

Authors:  Joshua M Thurman; Liudmila Kulik; Heather Orth; Maria Wong; Brandon Renner; Siranush A Sargsyan; Lynne M Mitchell; Dennis E Hourcade; Jonathan P Hannan; James M Kovacs; Beth Coughlin; Alex S Woodell; Matthew C Pickering; Bärbel Rohrer; V Michael Holers
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

10.  Metabolism of human beta 1H: studies in man and experimental animals.

Authors:  J A Charlesworth; D M Scott; B A Pussell; D K Peters
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.